Literature DB >> 22579669

New signalling pathway involved in the anti-proliferative action of vitamin D₃ and its analogues in human neuroblastoma cells. A role for ceramide kinase.

Francesca Bini1, Alessia Frati, Mercedes Garcia-Gil, Chiara Battistini, Maria Granado, Maria Martinesi, Marco Mainardi, Eleonora Vannini, Federico Luzzati, Matteo Caleo, Paolo Peretto, Antonio Gomez-Muñoz, Elisabetta Meacci.   

Abstract

1α,25-Dihydroxyvitamin D3 (1,25(OH)₂D₃), a crucial regulator of calcium/phosphorus homeostasis, has important physiological effects on growth and differentiation in a variety of malignant and non-malignant cells. Synthetic structural hormone analogues, with lower hypercalcemic side effects, are currently under clinical investigation. Sphingolipids appear to be crucial bioactive factors in the control of the cell fate: the phosphorylated forms, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), are mitogenic factors, whereas sphingosine and ceramide (Cer) usually act as pro-apoptotic agents. Although many studies correlate S1P function to impaired cell growth, the relevance of C1P/Cer system and its involvement in neuroblastoma cells remain to be clarified. Here, we demonstrated the anti-proliferative effect of 1,25(OH)₂D₃ as well as of its structural analogues, ZK156979 and ZK191784, in human SH-SY5Y cells, as judged by [³H]thymidine incorporation, cell growth and evaluation of active ERK1/2 levels. The inhibition of ceramide kinase (CerK), the enzyme responsible for C1P synthesis, by specific gene silencing or pharmacological inhibition, drastically reduced cell proliferation. 1,25(OH)₂D₃ and ZK191784 treatment induced a significant decrease in CerK expression and C1P content, and an increase of Cer. Notably, the treatment of SH-SY5Y cells with ZK159222, antagonist of 1,25(OH)₂D₃ receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevented the decrease of CerK expression elicited by 1,25(OH)₂D₃ supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in CerK regulation. Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)₂D₃ and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579669     DOI: 10.1016/j.neuropharm.2012.04.026

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  16 in total

1.  CERK inhibition might be a good potential therapeutic target for diseases.

Authors:  Wei-Li Yu; Yun Sun
Journal:  Br J Pharmacol       Date:  2015-03-16       Impact factor: 8.739

2.  CERK might contribute to inflammatory pain; Comments on Yu WL, Sun. Y (2015). CERK inhibition might be a good potential therapeutic target for diseases. Br J Pharmacol 172: 2165.

Authors:  Jin-lu Huang; Yan Huo; Li-li Wan; Quan-jun Yang; Jie Li; Cheng Guo
Journal:  Br J Pharmacol       Date:  2016-04       Impact factor: 8.739

Review 3.  Nuclear Lipids in the Nervous System: What they do in Health and Disease.

Authors:  Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Neurochem Res       Date:  2016-10-20       Impact factor: 3.996

Review 4.  Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system.

Authors:  Mercedes Garcia-Gil; Federica Pierucci; Ambra Vestri; Elisabetta Meacci
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

5.  Role of sphingosine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin.

Authors:  Alessia Frati; Barbara Ricci; Federica Pierucci; Silvia Nistri; Daniele Bani; Elisabetta Meacci
Journal:  Mol Endocrinol       Date:  2015-01

6.  Identification of an acid sphingomyelinase ceramide kinase pathway in the regulation of the chemokine CCL5.

Authors:  Benjamin Newcomb; Cosima Rhein; Izolda Mileva; Rasheed Ahmad; Christopher J Clarke; Justin Snider; Lina M Obeid; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-05-03       Impact factor: 5.922

Review 7.  Inhibitors for the Vitamin D Receptor-Coregulator Interaction.

Authors:  Kelly A Teske; Olivia Yu; Leggy A Arnold
Journal:  Vitam Horm       Date:  2015-11-30       Impact factor: 3.421

8.  Ceramide/protein phosphatase 2A axis is engaged in gap junction impairment elicited by PCB153 in liver stem-like progenitor cells.

Authors:  Roberta Squecco; Federica Pierucci; Eglantina Idrizaj; Alessia Frati; Elena Lenci; Catia Vicenti; Maria Chiara Iachini; Maria Martinesi; Rachele Garella; Maria Caterina Baccari; Fabio Francini; Elisabetta Meacci
Journal:  Mol Cell Biochem       Date:  2021-04-10       Impact factor: 3.396

Review 9.  Sphingomyelinase D/ceramide 1-phosphate in cell survival and inflammation.

Authors:  Io-Guané Rivera; Marta Ordoñez; Natalia Presa; Ana Gomez-Larrauri; Jorge Simón; Miguel Trueba; Antonio Gomez-Muñoz
Journal:  Toxins (Basel)       Date:  2015-04-29       Impact factor: 4.546

Review 10.  Re-configuration of sphingolipid metabolism by oncogenic transformation.

Authors:  Anthony S Don; Xin Y Lim; Timothy A Couttas
Journal:  Biomolecules       Date:  2014-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.